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OBJECTIVES The aim of this prospective study was to evaluate the role of programmed ventricular
stimulation (PVS) after noninvasive risk stratification to identify a subgroup of acute
myocardial infarction (AMI) survivors considered at risk for ventricular arrhythmias and
whether these patients could benefit from internal cardioverter-defibrillators (ICDs).
BACKGROUND The predictive value of noninvasive and invasive risk stratifiers after AMI has been
questioned. The question of whether the group of patients with inducible monomorphic
ventricular tachycardia (VT) after AMI could profit from ICD implantation is unanswered.
METHODS A consecutive series of 1,436 AMI survivors was screened noninvasively by Holter
monitoring, heart rate variability, ventricular late potentials, and ejection fraction. A subgroup
of 248 patients (17.3%) were identified as high-risk patients and scheduled for PVS. Due to
the study design, 54 patients .75 years were excluded; thus, 194 patients were eligible for
PVS. Triple extrastimuli at two paced cycle lengths (600 ms and 400 ms) were applied.
RESULTS In a subgroup of 98 (51%) high-risk patients, PVS was performed; 21 patients had an
abnormal response, and in 20 patients an ICD was implanted. During a mean follow-up of
607 days the arrhythmic event rate (sudden cardiac death, symptomatic VT, cardiac arrest)
was 33% with a positive electrophysiological test versus 2.6% (p , 0.0001) with a negative
electrophysiological test. A subgroup of 96 high-risk patients declined electrophysiological
study. In this nonconsent group, cardiac mortality (combined sudden and nonsudden) was
significantly higher (log-rank chi-square 9.38, p 5 0.0022, relative risk 4.7, 1.6 to 13.9)
compared to the group guided by electrophysiological testing and consecutive ICD implan-
tation.
CONCLUSIONS After a two-step risk stratification, PVS is helpful in selecting a subgroup of AMI survivors
without spontaneous ventricular arrhythmias who benefit from prophylactic ICD implanta-
tion. (J Am Coll Cardiol 2001;37:1901–7) © 2001 by the American College of Cardiology
Several studies, using both noninvasive and invasive
screening tests, have identified a relatively large number
of risk factors that predict the future occurrence of
arrhythmic events after acute myocardial infarction
(AMI) (1–12). Still, it is difficult to detect with a
sufficient sensitivity, specificity and predictive power
the subgroup of AMI survivors bound for future devel-
opment of ventricular tachycardia (VT) or ventricular
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fibrillation (VF) in the postdischarge period. Most studies
have demonstrated that programmed ventricular stimulation
(PVS) represents a strong marker of subsequent occurrence
of life-threatening ventricular tachyarrhythmias (11–16).
However, a large-scale or routine use of PVS as a risk
stratifier in survivors of an AMI has been restricted mostly
by its low predictive value (12). The disappointing results
with class I (17,18) and more recently class III antiarrhyth-
mic drugs (19–21) in survivors of an AMI have further
questioned the value of prophylactic antiarrhythmic treat-
ment in these patients. The recently proposed two-step
strategy in risk stratification of AMI survivors using non-
invasive and invasive tests (22,23) and the encouraging
results with internal cardioverter-defibrillators (ICDs) (24–
27) have paved the way for a realistic evaluation of the
indications and the value of PVS for arrhythmic risk
stratification after AMI.
Therefore, we addressed the question of whether PVS
could be used to identify with a sufficient predictive value a
subgroup of AMI survivors without spontaneous sustained
ventricular arrhythmias, previously identified as high-risk
patients by noninvasive screening tests, who are prone to
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future development of life-threatening ventricular arrhyth-
mias and whether this group of patients could profit from
ICD therapy.
METHODS
Patient population. A total of 1,436 patients with a
confirmed diagnosis of AMI were enrolled into a prospec-
tive risk-stratification study between December 1994 and
December 1999 at our hospital. Myocardial infarction was
diagnosed according to clinical, electrocardiographic
(ECG), and enzymatic criteria. All patients underwent
coronary angiography, and .90% of patients had a coronary
intervention (coronary angioplasty and/or stenting or
thrombolysis). In cases involving the narrowing of other
(noninfarct-related) arteries of .70%, concomitant angio-
plasty and/or stenting was performed the second week after
the acute event. Patients underwent a noninvasive risk-
stratification protocol that included measurement of left
ventricular ejection fraction, ventricular ectopy, and heart
rate variability in 24-h Holter ECG and detection of
ventricular late potentials by signal-averaged ECG before
discharge. Normal values for signal-averaged ECG (with
40-Hz high-pass filtering) were considered: the root-mean-
square voltage of the terminal 40 ms of the signal-averaged
complex .25 mV, duration of the low amplitude signals
(,40 mV) in the terminal 40 ms of the QRS complex
#40 ms, and duration of total filtered QRS complex
#115 ms. An abnormal signal-averaged ECG was defined
as abnormal values of one or more variables. In patients with
bundle branch block (22 patients) and prior implanted
pacemaker (1 patient), the signal-averaged ECG was not
performed.
Of the total patient population, 248 (17.3%) were iden-
tified as high-risk patients by this protocol and were
scheduled to undergo a PVS for further risk assessment and
possible ICD implantation. Table 1 shows the noninvasive
scoring system. Patients with a risk score $3 were consid-
ered high-risk and were advised to undergo invasive risk
stratification by PVS. Twenty-six patients in the entire
study population developed spontaneous monomorphic VT
in the subacute stage of their AMI (.24 h). Patients with
spontaneous monomorphic VT underwent electrophysio-
logical study and ICD implantation but are not included in
the study.
Electrophysiological study. An electrophysiological study
was performed the third week (median 18 days) after the
acute event. After written informed consent was obtained,
patients underwent PVS in the postabsorptive state while
receiving no antiarrhythmic drugs for a period of time .5
plasma half-lives. Electrode catheters were inserted percu-
taneously from the femoral groin and positioned in the heart
under fluoroscopic guidance at the atrioventricular junction
for His bundle recording and at the right ventricular apex.
Electrical stimulation of the heart was performed using an
external stimulator (UHS20, Biotronik, Berlin, Germany)
that produced rectangular impulses 2 ms in duration at twice
the diastolic threshold. Bipolar intracardiac electrograms
and 12-lead surface ECGs were simultaneously acquired
(BARD Labsystem, Lowell, Massachusetts). Intracardiac
electrograms were amplified, digitized at 1000 Hz, filtered
(30 to 500 Hz), and recorded into an optical disk.
Stimulation protocol. Stimulation protocol consisted of
triple extrastimuli (S2S3S4) delivered at two paced cycle
lengths (S1S1 600 ms and 400 ms) at the right ventricular
apex. Extrastimuli were applied after eight-beat drive trains
with a 3-s interdrive pause. Ventricular extrastimuli were
introduced beginning late in diastole and moved progres-
sively earlier in 10-ms steps until either ventricular refrac-
toriness or a coupling interval of 180 ms was reached. The
second (S3) and the third (S4) extrastimuli were delivered
after the S1S2 interval (S1S2 and S2S3 intervals for S4) was
fixed 50 ms longer than ventricular refractoriness of S2 and
S3, respectively. The protocol is terminated prematurely if a
sustained monomorphic VT with a cycle length $230 ms, a
sustained VT with a cycle length ,230 ms, or VF is
induced. Only sustained monomorphic VT with a cycle
length $230 ms was considered as an abnormal response.
The following definitions were employed: 1) sustained
monomorphic VT was a VT faster than 100 beats/min with
a regular rate and consistent beat-to-beat morphology that
lasted more than 30 s or required immediate termination
because of hemodynamic collapse; 2) nonsustained VT was
a run of six or more nonpaced ventricular beats that
terminated spontaneously within 30 s; 3) polymorphic VT
was a VT characterized by frequent changes in QRS
morphology and/or axis; and 4) VF was considered a
ventricular rhythm characterized by totally disorganized
activity and no discernible QRS complexes in the surface
ECG.
ICD implantation. The ICDs were implanted under local
anesthesia subcutaneously or subpectorally in the left sub-
clavian groove. The VVI-ICDs with antitachycardia pacing
capabilities of various manufacturers were used (CPI-
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ECG 5 electrocardiogram, electrocardiographic
ICD 5 internal cardioverter-defibrillator
PVS 5 programmed ventricular stimulation
RR 5 relative risk
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
Table 1. Noninvasive Risk Assessment
Risk Stratifier Cutoff Point(s) Score






Standard deviation of normal RR
intervals (ms)
$80/,80 0/1
Late potentials 2/1 0/1
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Guidant, Medtronic, Intermedics, Ventritex). The cutoff
rate for detection of VT and VF was set high (mean cycle
length 352 6 46 ms, mean cycle length 303 6 31 ms,
respectively) to avoid inappropriate activation of the device.
Follow-up. Follow-up information was obtained at the
time of revisits at the ambulatory arrhythmia clinic or by
telephone contact with patients and patients’ private physi-
cians. The end points of the follow-up period were death
and development of sustained ventricular tachyarrhythmias.
Patients with implanted ICDs were seen at one month after
discharge and then at three-month intervals throughout the
follow-up and whenever they reported palpitations or
shocks. During each follow-up visit, patients were examined
and devices interrogated to determine spontaneous episodes
with RR intervals and stored electrograms and the appro-
priateness of the delivered therapy. Modes of death were
established from written records and by interviewing wit-
nesses and/or attending physicians. Sudden cardiac death
was defined as instantaneous, unexpected death, death
within 1 h of the onset of symptoms or unexpected death
during sleep. Nonsudden cardiac death was considered to be
caused by progressive deterioration of the myocardial dys-
function. Deaths related to diseases in other systems were
considered noncardiac deaths. For the purpose of calcula-
tion of survival statistics, both the occurrence of docu-
mented sustained VT or VF (including information from
the interrogation of ICD after ICD interventions) and
sudden cardiac death were considered as arrhythmic events.
Statistical analysis. Data are presented as mean 6 SD,
percentage or range. Continuous variables were compared
by using the Mann-Whitney U test. Discrete variables were
compared by chi-square test or the Fisher exact test.
Survival curves were estimated using the Kaplan-Meier life
tables and were compared with a log-rank test. The Cox
proportional hazards survival model was used to calculate
the relative risk with use of betas (regression coefficients). A
p value ,0.05 was considered statistically significant.
RESULTS
Of the noninvasively, preselected 248 high-risk patients, 54
were older than age 75. According to the study design, only
patients of the high-risk group #75 years of age underwent
electrophysiological study. Thus, 194 patients (25 patients,
13% with an ejection fraction $40%) were eligible for
electrophysiological study and possible ICD implantation.
In 96 patients (49%) PVS was not performed. The reasons
for not performing electrophysiological study included re-
fusal from the patient, refusal from the patient’s private
physician, or other reasons.
Comparison of the patients with and without electro-
physiological testing. Programmed ventricular stimulation
was performed in 98 patients (51%). Clinical characteristics
of the patients who underwent electrophysiological study
and those who did not perform the test are given in Table
2. As seen from Table 2, there were no statistically signif-
icant differences related to sex, localization of AMI, coro-
nary interventions in the acute stage of AMI, risk factors for
coronary artery disease, extension of coronary artery disease,
follow-up therapy, degree of noninvasively defined risk
(score points), and overall arrhythmic event rates. However,
electrophysiologically tested patients were younger, had a
higher peak creatine kinase level and a lower incidence of
sudden cardiac death and overall cardiac mortality (sudden
and nonsudden) as compared with the group in whom the
electrophysiological study was not performed.
Results of PVS. Results of PVS are shown in Table 3.
Sustained monomorphic VT was evoked in 21 patients
(22%). All other responses were considered as nonspecific.
Clinical characteristics of the patients with an abnormal
Table 2. Clinical Characteristics of Patients Who Underwent







Age (yrs) 58 6 11 62 6 10 0.02
Women 18 (18)* 11 (12) 0.18
Peak CK (U/liter) 1,836 6 1,401 1,434 6 1,281 0.05
Ejection fraction (%) 32 6 8 33 6 8 0.23
Anterior AMI 64 (65) 56 (58) 0.32
PTCA/Stenting 90 (92) 81 (84) 0.11
Thrombolysis 7 (7) 5 (5) 0.58
CAD extension** 2 6 0.85 2 6 0.88 0.78
Old MI 22 (22) 27 (28) 0.36
History of bypass operation 10 (10) 6 (6) 0.32
Arterial hypertension 67 (68) 57 (59) 0.19
Hypercholesterolemia 63 (64) 65 (68) 0.61
Diabetes mellitus 19 (19) 27 (28) 0.15
Smoking 60 (61) 52 (54) 0.32
Familial history for CAD 22 (22) 16 (17) 0.31
Beta-blocking agents 87 (89) 79 (82) 0.20
ACE inhibitors 92 (94) 85 (89) 0.19
Diuretic drugs 73 (74) 66 (69) 0.38
Digitalis 2 (2) 1 (1) 0.99
Nitrates 11 (11) 16 (17) 0.27
Aspirin 98 (100) 92 (96) 0.35
Statins 73 (74) 74 (77) 0.67
Score points 4 6 0.9 4 6 0.7 0.19
Arrhythmic events 9 (9)† 9 (9) 0.96
Sudden cardiac death 1 (1) 9 (9) 0.009
Cardiac mortality 4 (4) 17 (18) 0.002
*Numbers in parentheses represent percentage. **Number of coronary arteries with
significant narrowings (.50%). †One patient was successfully resuscitated.
ACE 5 angiotensin-converting enzyme; AMI 5 acute myocardial infarction;
CAD 5 coronary artery disease; CK 5 creatine kinase; ICD 5 internal cardioverter-
defibrillator; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal
coronary angioplasty.
Table 3. Results of Electrophysiological Study
Response to Programmed Stimulation n
Sustained monomorphic VT with a cycle length $230 ms
(mean rate 216 6 33 beats/min) 21
Fast sustained VT with a cycle length ,230 ms
(mean rate 278 6 11 beats/min) 7
Polymorphic VT 12
No responses or nonsustained VT 51
Ventricular flutter/fibrillation 7
VT 5 ventricular tachycardia.
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response versus those with a nonspecific response or nega-
tive study are depicted in Table 4. Patients with an
abnormal response were older and had a significantly higher
incidence of arrhythmic events during follow-up. All other
clinical characteristics were equally distributed between the
two groups. No vascular or thrombotic complications were
observed during electrophysiological study. In 20 patients
with an abnormal response, ICDs were implanted 5 6 4
days (median 3 days; interquartile range 2 to 6 days) after
the electrophysiological study.
Follow-up data. Patients were followed for 607 6 424
days (up to 1,717 days). During the follow-up period there
were altogether 24 deaths (12%). Of these, 21 deaths were
of cardiac origin, whereas 3 deaths were of noncardiac
origin. Of the cardiac deaths, 10 were sudden cardiac deaths
(1 death in the group with a negative electrophysiological
study and 9 deaths in the group not tested electrophysi-
ologically). Eleven deaths were nonsudden (3 deaths in the
group with electrophysiological study and 8 deaths in the
group not tested electrophysiologically). Thus, sudden car-
diac death (1% vs. 9%, p 5 0.009) and overall cardiac
mortality (4% vs. 18%, p 5 0.002) were significantly higher
in the group not tested electrophysiologically as compared
to the group that underwent electrophysiological study and
ICD implantation in cases of an abnormal response. Three
deaths of noncardiac origin occurred in the group not tested
electrophysiologically.
Predictive value of PVS and intervention of ICD. In 7 of
21 patients with an implanted ICD (33%), the ICD
interventions as shock discharge (4 patients), antitachycar-
dia pacing (2 patients), or both (1 patient) were recorded.
Analysis of stored electrograms revealed that detected ar-
rhythmia at the time of ICD intervention was monomor-
phic VT (6 patients) and polymorphic VT (1 patient).
Arrhythmic event rate (sustained ventricular arrhythmias
causing ICD intervention plus sudden cardiac death) was
significantly higher in the group with a positive electrophys-
iological test plus ICD implantation as compared with the
group with a negative electrophysiological test (33% vs.
2.6%, p , 0.0001). Patients who suffered an arrhythmic
event had a lower ejection fraction than those who did not
experience such events (24.5 6 6.9% vs. 33.2 6 7.6%, p ,
0.001). No arrhythmic events occurred in the 26 patients
with a nonspecific response after PVS.
Survival analysis and relative risk estimation. The
Kaplan-Meier survivorship curves for arrhythmic events in
patients with a positive electrophysiological test plus ICD
implantation and the patients with a negative electrophys-
iological test are presented in Figure 1A. It can be seen from
the survivorship curves that significant differences existed in
the incidence of arrhythmic events in patients with a
positive test versus those with a negative test (log-rank
chi-square 18, p , 0.0001) and that the majority of events
occurred during the first year of follow-up. Relative risk
(RR) was 13.8 (2.9 to 66.3). Figure 1B shows the Kaplan-
Meier survivorship curve for cardiac mortality (combined
sudden and nonsudden) in the group that underwent
electrophysiological testing and ICD implantation (patients
with a positive test) versus the group that was not tested
electrophysiologically. Again, significant differences were
seen in the cardiac mortality rates between the two groups
(log-rank chi-square 9.38, p 5 0.0022, RR 4.7 [1.6 to
13.9]), with the majority of deaths occurring in the first year
of follow-up. Survivorship analysis showed that the risk
score had an inverse relationship with arrhythmia-free
interval (Fig. 2).
DISCUSSION
The use of PVS after AMI. The mortality rate in the first
year after AMI is about 10%, and there is a continuing
mortality in the subsequent years of 4% per annum (28). It
Table 4. Clinical Characteristics of Patients With a Positive and Negative Electrophysiological
(EP) Study
Positive EP
Study (n 5 21)
Negative EP
Study (n 5 77)
p
Value
Age (yrs) 63 6 8 57 6 11 0.02
Women 4 (19) 14 (18) .0.99
Ejection fraction (%) 31 6 9 32 6 8 0.62
Peak CK (U/liter) 1,872 6 1,589 1,826 6 1,361 0.90
Anterior MI 16 (76) 48 (62) 0.24
PTCA/Stenting 19 (90) 71 (92) 0.80
Thrombolysis 1 (5) 6 (8) 0.63
CAD extension 2 6 0.83 2 6 0.86 0.59
History of bypass operation 3 (14) 7 (9) 0.49
Arterial hypertension 16 (76) 51 (66) 0.38
Hypercholesterolemia (.240 mg/dl) 14 (67) 49 (64) 0.79
Diabetes mellitus 4 (19) 15 (19) 0.96
Smoking 11 (52) 49 (64) 0.35
Familial history for CAD 2 (10) 20 (26) 0.11
Score points 4 6 0.9 4 6 0.85 0.20
Arrhythmic events during follow-up 7 (33) 2 (2.6) ,0.0001
Abbreviations as in Table 2.
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has been estimated that the majority of these deaths are
caused by ventricular tachyarrhythmias (29). Based on the
assumption that PVS tests the ability of a potential arrhyth-
mogenic substrate to maintain the sustained reentrant exci-
tation, this technique has been used in numerous studies for
arrhythmic risk stratification after AMI. However, conflict-
ing results regarding the predictive power (30–33), debate
over whether comparable information can be taken from a
combination of noninvasive tests (34,35), low predictive
value (11), and the invasive nature associated with potential
morbidity (36) have all prevented large-scale use of PVS as
a screening tool in patients after AMI. Furthermore, the use
of PVS as a screening test after an AMI is marked by such
substantial methodological differences that comparison of
studies is almost impossible. The current opinion is, how-
ever, that PVS prognosticates the subsequent development
of life-threatening ventricular arrhythmias after AMI, and it
should have a role in clinical practice to screen high-risk
patients for arrhythmia development after AMI.
Main findings of our study. The main findings of our
study can be summarized as follows: 1) The combined use of
a series of noninvasive tests such as left ventricular ejection
fraction, signal-averaged ECG, and Holter monitoring with
heart rate variability analysis can effectively preselect a
subgroup of patients, among the patients without sponta-
neous occurrence of VT or VF in the acute phase of AMI,
at sufficiently high risk (17% of the total AMI population in
this study), to warrant the use of PVS as a risk stratifier.
This two-step strategy significantly reduces the number of
patients exposed to PVS and to its possible side effects. 2) A
positive electrophysiological study had a 33% predictive
power to identify patients (7 in 21 patients) that developed
VT during follow-up.
In contrast, a negative electrophysiological study identi-
fies a group of patients who have a less than 3% (2 in 77
patients) chance of developing sudden cardiac death in
nearly two years after index event. Of note, none of the
26 patients (26%) with inducible fast sustained VT (cycle
length ,230 ms), polymorphic VT or VF developed life-
threatening ventricular arrhythmias during the mean
follow-up of almost two years. This corroborates data
from an earlier large-scale Australian study in 1,209 AMI
survivors undergoing PVS (11). Previous studies (22,37),
but not a recent one (23), have reported a significant
increase in the positive predictive value using a two-step
strategy in the risk-stratification process. Pedretti et al. (22)
and Zoni-Berisso et al. (37) reported an increase of positive
predictive value from 30% to 65% and from 10% to 66%,
respectively.
Conversely, Andresen et al. (23) reported an 18% predic-
tive value after using a two-step strategy for arrhythmic risk
stratification after AMI. However, in the Andresen et al.
(23) study only two premature beats during PVS were used,
thus limiting the sensitivity and predictive value of PVS as
already shown by Bourke et al. (11). Overall, differences in
the noninvasive tests used, number of extrastimuli, defini-
tion of an abnormal response at electrophysiological study,
and time of electrophysiological study after AMI could
account for the existing differences between our study and
their study (23). 3) Survivors of an AMI without sponta-
neous sustained ventricular arrhythmias, defined as a high-
risk group by noninvasive tests and with inducible sustained
monomorphic VT, profit from ICD therapy. A significant
reduction of sudden cardiac death was observed in the group
that was tested electrophysiologically with consecutive ICD
implantation in cases of an abnormal response to PVS
compared to patients that were not electrophysiologically
assessed (1% vs. 9%, p 5 0.009).
Before considering this group of patients as suitable
candidates for an ICD therapy, we specifically address the
aggressiveness of the coronary interventions in the acute
Figure 1. (A) Kaplan-Meier curve for arrhythmic events in patients with a
negative electrophysiological test versus patients with a positive electro-
physiological test plus internal cardioverter-defibrillator (ICD) implanta-
tion. (B) Kaplan-Meier survivorship curve for cardiac mortality (combined
sudden and nonsudden) in the group that underwent electrophysiological
testing plus ICD implantation versus the group of patients not tested
electrophysiologically (no-consent group). PVS 5 programmed ventricular
stimulation.
Figure 2. Kaplan-Meier survivorship curve for arrhythmic events in pa-
tients with different risk scores. LVEF 5 left ventricular ejection fraction.
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phase of AMI. With .90% coronary intervention rate
(coronary angioplasty and/or stenting and thrombolysis) our
patients could represent a group with the best characteriza-
tion of arrhythmogenic substrate to date. Concomitantly
with dilation and/or stenting of occluded artery, other
arteries with narrowings $70% were also treated. These
revascularization interventions, by restoring coronary
blood flow, could have reduced the extent of existing
chronic ischemia or the rate of repeated acute ischemic
events. That the presence of chronic ischemia could affect
the ICD therapy is demonstrated by the results of the
CABG-Patch trial (38), which failed to demonstrate ben-
efits of ICD therapy. In addition, results of the CABG-
Patch trial—in which patients were screened on the basis of
low ventricular ejection fraction and the presence of ven-
tricular late potentials—justify maximal efforts, including
invasive screening and interventions to characterize the
arrhythmogenic substrate in order to increase the benefits of
ICD therapy.
Study limitations. Although a total of 194 patients were
eligible for electrophysiological study, only 98 of them
(51%) were assessed with ventricular stimulation. This result
was predominantly due to reluctance to undergo this inva-
sive test once its research nature was explained. Addition-
ally, the absence of spontaneous arrhythmias could also have
influenced the decision to undergo the test from both
patients and patients’ private physicians. Other studies have
also reported a reluctance of a large proportion of the
patients to undergo electrophysiological study after suffering
an AMI (11,34). The patients not studied with ventricular
stimulation were similar to the patients that were assessed
with ventricular stimulation for most of the characteristics,
including ejection fraction, degree of noninvasively defined
arrhythmic risk, extension of coronary artery disease, and
drug therapy during follow-up. Nevertheless, the nonran-
domized nature of our study could not exclude some bias,
especially in encouraging the patients to undergo the test.
The accuracy of collecting the follow-up information is
different in patients with implanted ICD compared to
patients without implanted ICD. In patients with im-
planted ICD, the analysis of arrhythmic events was based on
interrogation of ICD. In the patients without ICD, analysis
of arrhythmic events was based on traditional definitions.
Thus, some nonfatal ventricular arrhythmias could have
escaped from documentation in groups without implanted
ICD.
Conclusions. The use of PVS is helpful in selecting a
subgroup of AMI survivors without spontaneous occurrence
of sustained ventricular arrhythmias, defined as a high-risk
group based on noninvasive screening tests that could profit
from ICD therapy. A two-step risk-stratification strategy
substantially reduces the number of patients who have to
undergo PVS. This stratification strategy increases substan-
tially the predictive value of PVS for future development of
life-threatening ventricular arrhythmias in survivors of AMI
and warrants prophylactic ICD implantation in light of
induction of sustained monomorphic VT.
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